Glanzmann's thrombasthenia secondary prevention: Difference between revisions
No edit summary |
|||
| Line 9: | Line 9: | ||
==Secondary Prevention== | ==Secondary Prevention== | ||
[[DDAVP]] prevents [[bleeding]] after [[dental extraction]] and minor [[surgery]] in patients with milder [[platelet]] defects<ref name="pmid11925531">{{cite journal |vauthors=Piot B, Sigaud-Fiks M, Huet P, Fressinaud E, Trossaërt M, Mercier J |title=Management of dental extractions in patients with bleeding disorders |journal=Oral Surg Oral Med Oral Pathol Oral Radiol Endod |volume=93 |issue=3 |pages=247–50 |date=March 2002 |pmid=11925531 |doi= |url=}}</ref><ref name="pmid10472549">{{cite journal |vauthors=Kosch A, Kehrel B, Nowak-Göttl U, Häberle J, Jürgens H |title=[Thrombocytic alpha-delta-storage-pool-disease: shortening of bleeding time after infusion of 1-desamino-8-D-arginine vasopressin] |language=German |journal=Klin Padiatr |volume=211 |issue=4 |pages=198–200 |date=1999 |pmid=10472549 |doi=10.1055/s-2008-1043787 |url=}}</ref>. [[Glanzmann's thrombasthenia]] patients need regular [[dental]] visits and must maintain good [[oral hygiene]] because the recurrence of [[gingival bleeding]] is more in them. These patient should avoid contact sports. [[Estrogens]], [[Platelet transfusions|platelet transfusion]], [[antifibrinolytic]] agents, and recombinant human factor VIIa are some other therapies used for treatment/prevention. | [[DDAVP]] prevents [[bleeding]] after [[dental extraction]] and minor [[surgery]] in patients with milder [[platelet]] defects<ref name="pmid11925531">{{cite journal |vauthors=Piot B, Sigaud-Fiks M, Huet P, Fressinaud E, Trossaërt M, Mercier J |title=Management of dental extractions in patients with bleeding disorders |journal=Oral Surg Oral Med Oral Pathol Oral Radiol Endod |volume=93 |issue=3 |pages=247–50 |date=March 2002 |pmid=11925531 |doi= |url=}}</ref><ref name="pmid10472549">{{cite journal |vauthors=Kosch A, Kehrel B, Nowak-Göttl U, Häberle J, Jürgens H |title=[Thrombocytic alpha-delta-storage-pool-disease: shortening of bleeding time after infusion of 1-desamino-8-D-arginine vasopressin] |language=German |journal=Klin Padiatr |volume=211 |issue=4 |pages=198–200 |date=1999 |pmid=10472549 |doi=10.1055/s-2008-1043787 |url=}}</ref>. [[Glanzmann's thrombasthenia]] patients need regular [[dental]] visits and must maintain good [[oral hygiene]] because the recurrence of [[gingival bleeding]] is more in them. These patient should avoid contact sports. [[Estrogens]], [[Platelet transfusions|platelet transfusion]], [[antifibrinolytic]] agents, and recombinant human factor VIIa are some other therapies used for treatment/prevention. <ref name="pmid24910701">{{cite journal |vauthors=Varkey I, Rai K, Hegde AM, Vijaya MS, Oommen VI |title=Clinical Management of Glanzmann's Thrombasthenia: A Case Report |journal=J Dent (Tehran) |volume=11 |issue=2 |pages=242–7 |date=March 2014 |pmid=24910701 |pmc=4043557 |doi= |url=}}</ref><ref name="pmid26185478">{{cite journal |vauthors=Solh T, Botsford A, Solh M |title=Glanzmann's thrombasthenia: pathogenesis, diagnosis, and current and emerging treatment options |journal=J Blood Med |volume=6 |issue= |pages=219–27 |date=2015 |pmid=26185478 |pmc=4501245 |doi=10.2147/JBM.S71319 |url=}}</ref><ref name="pmid16427383">{{cite journal |vauthors=Poon MC, Zotz R, Di Minno G, Abrams ZS, Knudsen JB, Laurian Y |title=Glanzmann's thrombasthenia treatment: a prospective observational registry on the use of recombinant human activated factor VII and other hemostatic agents |journal=Semin. Hematol. |volume=43 |issue=1 Suppl 1 |pages=S33–6 |date=January 2006 |pmid=16427383 |doi=10.1053/j.seminhematol.2005.11.009 |url=}}</ref> | ||
==References== | ==References== | ||
Revision as of 19:44, 13 December 2018
|
Glanzmann's thrombasthenia |
|
Differentiating Glanzmann's thrombasthenia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Glanzmann's thrombasthenia secondary prevention On the Web |
|
American Roentgen Ray Society Images of Glanzmann's thrombasthenia secondary prevention |
|
Risk calculators and risk factors for Glanzmann's thrombasthenia secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Omer Kamal, M.D.[2], Niyousha Danesh, MD-MPH
Overview
DDAVP prevents bleeding after dental extraction and minor surgery in patients with milder platelet defects. Glanzmann's thrombasthenia patients need regular dental visits and must maintain good oral hygiene because the recurrence of gingival bleeding is more in them. These patient should avoid contact sports. Estrogens, platelet transfusion, antifibrinolytic agents, and recombinant human factor VIIa are some other therapies used for treatment/prevention.
Secondary Prevention
DDAVP prevents bleeding after dental extraction and minor surgery in patients with milder platelet defects[1][2]. Glanzmann's thrombasthenia patients need regular dental visits and must maintain good oral hygiene because the recurrence of gingival bleeding is more in them. These patient should avoid contact sports. Estrogens, platelet transfusion, antifibrinolytic agents, and recombinant human factor VIIa are some other therapies used for treatment/prevention. [3][4][5]
References
- ↑ Piot B, Sigaud-Fiks M, Huet P, Fressinaud E, Trossaërt M, Mercier J (March 2002). "Management of dental extractions in patients with bleeding disorders". Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 93 (3): 247–50. PMID 11925531.
- ↑ Kosch A, Kehrel B, Nowak-Göttl U, Häberle J, Jürgens H (1999). "[Thrombocytic alpha-delta-storage-pool-disease: shortening of bleeding time after infusion of 1-desamino-8-D-arginine vasopressin]". Klin Padiatr (in German). 211 (4): 198–200. doi:10.1055/s-2008-1043787. PMID 10472549.
- ↑ Varkey I, Rai K, Hegde AM, Vijaya MS, Oommen VI (March 2014). "Clinical Management of Glanzmann's Thrombasthenia: A Case Report". J Dent (Tehran). 11 (2): 242–7. PMC 4043557. PMID 24910701.
- ↑ Solh T, Botsford A, Solh M (2015). "Glanzmann's thrombasthenia: pathogenesis, diagnosis, and current and emerging treatment options". J Blood Med. 6: 219–27. doi:10.2147/JBM.S71319. PMC 4501245. PMID 26185478.
- ↑ Poon MC, Zotz R, Di Minno G, Abrams ZS, Knudsen JB, Laurian Y (January 2006). "Glanzmann's thrombasthenia treatment: a prospective observational registry on the use of recombinant human activated factor VII and other hemostatic agents". Semin. Hematol. 43 (1 Suppl 1): S33–6. doi:10.1053/j.seminhematol.2005.11.009. PMID 16427383.